FDA approves Bristol-Myer's skin cancer drug

(Reuters) - The U.S. Food and Drug Administration granted an accelerated approval to Bristol-Myers Squibb Co's drug for an advanced form of skin cancer. The drug, Opdivo, inhibits the action of the protein PD-1, which prevents the body's immune system from attacking melanoma tumors. The FDA's approval comes well before its scheduled review date of March 30. (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Kirti Pandey)



via Health News Headlines - Yahoo News http://ift.tt/16JY5r5